You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Netris pancreatic cancer study doses first patient

Netris Pharma – a company focused on receptor biology – has revealed that the first patient has been dosed during a multi-location, proof-of-concept trial.